Evidence map›Paper›PMID 30306414›Full record

ArticleCognitive, affective & behavioral neuroscience2019

Dopaminergic influences on risk preferences of Parkinson's disease patients.

Shunsuke Kobayashi, Kohei Asano, Nozomu Matsuda, Yoshikazu Ugawa

Abstract read
PubMed Publisher
In one paragraph

Article in Cognitive, affective & behavioral neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Weighing Open Science Against Research Participation Burden in Informed Consent: A Randomized Pilot Study.Journal of empirical research on human research ethics : JERHRE · 2025
    Trial
  5. Trial
  6. Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shunsuke KobayashiDepartment of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima-shi, Fukushima-ken, 960-1295, Japan. skoba-tky@umin.net.
Kohei AsanoKokoro Research Center, Kyoto University, Kyoto, Japan.
Nozomu MatsudaDepartment of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima-shi, Fukushima-ken, 960-1295, Japan.
Yoshikazu UgawaDepartment of Neurology, Fukushima Medical University, 1 Hikarigaoka, Fukushima-shi, Fukushima-ken, 960-1295, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinicians are increasingly recognizing impulse control disorders (ICDs) as a complication of dopaminergic treatment in Parkinson's disease (PD). Considering the pivotal role of dopamine in reward information processing, ICDs may originate from dysregulation of reward-oriented behavior, and the behavioral changes may be reflected in shifts of psychological risk preference during decision-making. We used a behavioral economics paradigm to evaluate quantitatively the risk preferences of PD patients in levodopa on and off states. We also examined age-matched healthy controls. We found that levodopa increased the subjective value and prolonged the decision time in PD patients. These effects are apparently not explained by kinematic improvements but are attributed to psychological shifts of risk preferences and increased attention during risky decision-making. The risk preferences of healthy controls were similar to those of PD on levodopa treatment. The risk preferences of PD patients were not correlated with the scores of routine cognitive batteries, suggesting that dopamine-sensitive risk preferences are independent of cognitive capacities as measured by conventional batteries, including general intelligence, memory, and frontal functioning. By contrast, apathy and ICD partially predicted the risk attitude in PD patients, suggesting a common background of limbic origin behind these properties. The present results demonstrated that dopamine deficiency in off-state PD leads to risk-avoiding behavior and levodopa treatment increases the risk preferences. Behavioral economics framework is useful to evaluate short-term psychological changes in response to levodopa in PD patients.

Indexed as

RewardAgedCognitionDecision MakingDisruptive, Impulse Control, and Conduct DisordersDopamineDopamine AgonistsFemaleHumansMaleMiddle AgedParkinson DiseaseTask Performance and AnalysisDopamineDopamine AgonistsCoefficient of relative risk aversionImpulse control disordersLevodopaNeuroeconomicsParkinson’s diseasePathological gambling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.